Try our Advanced Search for more refined results
Life Sciences - January, 2022
311 articles
- Taiwanese Pharma Co. Beats Sanctions In AOP Arb. Fight
- Opioid Pills Set Off 'Triple Wave' Of Addiction, Judge Hears
- 9th Circ. Won't Review DEA Letter On Medical Psilocybin Use
- UK Bill Would Waive IP On Pandemic Vaccines, Treatments
- ICE Detainees Seek Booster Shots For Medically Vulnerable
- Celgene, Dr. Reddy's Settle Generic Cancer Drug Row
- Elite Trial Lawyer Switches Sides To A Changing Plaintiffs Bar
- Feds Tell Jury Ex-Drug Co-Op CEO To Blame For Opioid Crisis
- Moderna COVID-19 Vaccine Gets FDA's Full OK
- Mylan Says Fed. Circ. Must Nix Ruling That Upheld Biogen IP
- Pharmacies Can't Get 6th Circ. Review In Ohio Opioid Trial
- Keys To Keeping Law Firm Talent Amid The Great Resignation
- Cardinal Health Pays $13M To Settle Doctor Kickback Claims
- Investors In Pot Co. Aphria Seek Class Cert. In $144M Suit
- Medtronic Accused Of Stealing Rival's Sales Reps, Customers
- Cancer-Focused Biotech Co. Plans $132M IPO In Cold Market
- Medical Imaging CEO Gets 5 Years In Prison For $250M Fraud
- CVS Drug Buyers Ask 9th Circ. For Redo Of $121M Trial
- Patent Specification Concerns Make IPRs Tricky For Drug Cos.
- Drugmakers Won't Get Discovery From Valisure In Zantac MDL
- Indivior Asks Fed. Circ. To Rethink Ax Of Suboxone Patent
- Purdue's Appeal On Ch. 11 Releases Fast-Tracked By 2nd Circ.
- Lab Owners Aim To Duck $24M Medicaid Overpayment Claims
- Immigration Policy Changes Are A Boon To STEM Employers
- Arizona Judge Is Latest To Block Contractor Vax Mandate
- Health Hires: Manatt, Garfunkel Wild
- Ex-CDC Worker's Bias Suit Should Get Spiked, Judge Says
- Pa. Worker Claims He Was Fired For Medical Pot Use
- Alston & Bird Nabs Former FDA Associate Chief Counsel
- Strategies For Coping With Stress In The Legal Profession
- 4 Highlights In Breyer's Legal Legacy For Health, Life Sciences
- Teva Gets Nod For $420M Price-Fixing Deal With Investors
- Fed. Circ. Judge Knocks Justices' Assignor Estoppel Ruling
- 6 Breyer Product, Personal Injury Opinions Attys Should Know
- Judge Says Shkreli's Picasso Can Be Sold To Pay $2.6M Debt
- Walmart Seeks Toss Of Suit Over Crash That Killed Girl Scouts
- The Term: Breyer's Legacy And The Nomination To Come
- Breyer Retiring As Supreme Court Lurches Right
- SymBiosis Claims Biotech Firm's Fraud Led To Its Investment
- 'Street Level' Oxy Pusher Admits Tricking Ex-CEO's Company
- All Pa. Counties Join $26B Opioid Deal Over DAs' Objections
- AGs Ask OSHA For Climate Change Heat Standards
- What You Need To Know About Judge Jackson
- Biden At His Side, Justice Breyer Announces Retirement
- 7th Circ. Dismisses Indiana Univ. Students' Vax Mandate Suit
- Democrats Plan Swift Confirmation Of Breyer Successor
- Fla. Judge Vacates Arbitration Award Over Deposition Texting
- 4th Circ. Backs Toss Of FCA Medicaid Suit Against Allergan
- Mississippi Lawmakers Send Medical Pot Bill To Governor
- EPA Declines To Switch Up Ethylene Oxide Risk Calculation
- Meet The Possible Nominees For Justice Breyer's Seat
- How AI Can Transform Crisis Management In Litigation
- 'Just Do Your Job': Justice Breyer's Legacy Of Pragmatism
- ITC Investigating Alvotech's Humira Biosimilar Imports
- Tribal Corp. IP Suit Highlights Sponsored Research Pitfalls
- 5 Breyer Opinions You Need To Know
- Justice Breyer To Retire From High Court
- Digital Medicine Co. Akili Valued At $1B Via SPAC Merger
- 'Frankly Stunning': Distributors Pan DEA Vet At Opioid Trial
- NY Court Reporters Challenge Courthouse Vax Mandate
- Two Investor Settlements From 2021 Crack Top 100 List
- How Vaccine Mandates Impact Employment Insurance Policies
- Zetia Buyers Should Be Denied Class Cert., Court Told
- Mallinckrodt, Fresenius Reach $14M Deal On Supply Claims
- Rhode Island Inks $91M Opioid Deal With Distributors
- The Insys Case Made History. Why An Exec's Appeal May Not
- Supervisor Relationships Are Key To Beating Atty Burnout
- How New Laws Could Tighten FDA Regulation Of Cosmetics
- AstraZeneca Urges Fed. Circ. To Rethink IP Ruling For Mylan
- Supplement Biz Says Rival Lies About Toxic Ingredients
- Distributor Urges 6th Circ. To Revive Opioid Coverage Suits
- Beyond Big: Smaller, Hyperfocused Firms Still Stand Out
- Bridgepoint Inks $7B Sale Of Material Testing Co. To Temasek
- Drug Distributors' Order Reporting Had Flaws, Expert Testifies
- Calif. Pot Seller's Bid To Nix Conviction Fails At High Court
- Fed. Circ. Upholds Patent App Injunction In Trade Secret Row
- Inovio Fights Investor Class Cert. In COVID-19 Vaccine Suit
- 1st Circ. Affirms Broad Gov't Power To End FCA Suits
- Pharma Cos. Get Bystolic Generic Delay Claims Tossed
- Lionbridge Defeats TransPerfect's Trade Secrets Suit
- Ex-Compliance Boss Walks Fine Line At Oxy Conspiracy Trial
- Calfee Halter Adds 4 IP Attys From Cleveland Boutique
- The Leaderboard: Tracking A Firm's Litigation Footprint
- COVID Fuels Top Firms' Priorities In 2022
- Judge Dyk Explains Takeda Loss In IP Fight Over Hemlibra
- Texas Judge Blocks Vaccine Mandate For Federal Workers
- Ga. Judge Grapples With Pot's Legal Status In Licensing Fight
- IPO Market Gets Off To A Rocky Start In 2022
- Roundup Buyers Seek Up To $45M Economic Loss Settlement
- District Court Won't Hear J&J Talc Unit's Ch. 11 Stay Fight
- $26B Deal Keeps Opioid Files Of J&J, Distributors Out Of View
- DOJ Sues Pharmacist For Filling Illegal Opioid Prescriptions
- How Magistrate Judges Can Help Tame Large Product MDLs
- 'Data-Rich' Sources Can ID Niaspan Class, 3rd Circ. Told
- Lessons From Moderna's COVID Vaccine Patent Dispute
- Slayback Gets PTAB To Wipe Out Schizophrenia Treatment IP
- CORRECTED: College Ex-Dean Admits $651K Fraud Against Student Org.
- Fed. Circ. Backs Toss Of MRI Patent Suit Against Government
- Hedge Fund Priest Fights SEC Ban After Mixed Fraud Verdict
- Paul Hastings Expands DC Life Sciences Consulting Group
- IP Forecast: Minerva, Hologic To Face Off At Fed. Circ. Again
- AOP Orphan Accuses PharmaEssentia Of Arbitration Fraud
- Invisalign Maker Gets PTAB To Invalidate Dental Scanner IP
- EPA Says Fuel Importer Violated Clean Air Act
- Commerce Finalizes Duties On Russian, Indian Polymers
- Feds Urge High Court To Back Doctors' Opioid Convictions
- Covid Tester Escalates BCBS Pay Fight With Antitrust Claims
- Clinical Trial Staffer Gets 30 Months For Research Fraud
- Hemp Group Tells DC Circ. To Keep DEA Hands Off 'Hot' Crops
- GAO Unclear If HHS Is Prepared For Full COVID Vax Duties
- Alsup Mulls $113M Atty Fees In $454M Glumetza Antitrust Deal
- Drug Patent Suits' Novel Theory Tests False Claims Act Limits
- Investors Say Biotech Co. Altered Alzheimer Drug Data
- 4 Consequences Of Gov't Contractor Antitrust Violations
- Latham, Davis Polk Guide Psychedelic Co.'s SPAC Merger
- Venture Wants Atty Fees Over CBD Cream Patent Row
- 6 Maura Healey Cases To Know As Gov. Campaign Launches
- Deals Rumor Mill: Zentiva, Carlyle Group, Acorns Grow
- Starbucks Nixes Vax Rule After High Court Sinks OSHA Order
- Mississippi House Passes Medical Marijuana Legalization Bill
- Sanofi Tells 10th Circ. It Paid $36M To Access EpiPen Market
- Appeals Board Won't Hear Software License Breach Dispute
- Emails In Ex-CEO's Oxy Trial Cut Both Ways On Compliance
- The Hottest FCA Cases And Trends To Watch In 2022
- Access Bio Accused Of Breaching $120M COVID Test Kit Deal
- Drugmakers Want Discovery From Valisure In Zantac MDL
- Ill. COVID-19 Testing Cos. Falsified Results, Minn. AG Says
- What's Next For COVID-Era Emergency Use Medical Devices
- Kaiser Says First-To-File Bar Breaks $1B Medicare Fraud Suits
- FTC Cracks Down On COVID Ad Claims Amid Omicron Surge
- The Rising Demand For Commercial Litigators In 2022
- Canadian Model Wants $50M Allergan Unit Suit To Proceed
- NJ Bankruptcy Judge Undoes Split Of J&J Tort Committee
- Marketer Says Racial Bias Drove Pa. Lab's Contract Breach
- No New Trial For Smith & Nephew Hip Implant Patient
- Feds Want 1st Circ.'s Guidance After Jailed Biotech CEO Dies
- Covington, Latham Craft UCB's Zogenix Buy Of Up To $1.9B
- Purdue Urges 2nd Circ. To Quickly Undo Ch. 11 Plan Rejection
- Gilead Says Counterfeit Ring Swiped Its HIV Drug Branding
- Pharma Biz Lied About COVID-19 Drug's Prospects, Suit Says
- Endo's Newest Opioid Deal Earmarks $65M For Fla.
- Tyson Can't Escape COVID-19 Mandate Suit, Workers Say
- Tribe Says Its Opioid Suit Was Not Harmed By Dropped Claim
- Pharma Co. Gets Partial Win In Cancer Drug Contract Fight
- Antitrust's 1900s Nostalgia In The US And Beyond
- Cancer Nonprofit Exec Embezzled $3.7M, Feds Say
- Unvaccinated Ex-Aegerion Rep Can't Delay 4-Year Fraud Term
- Teva Reaches $420M Deal To End Investors' Price-Fixing Suit
- Ex-CEO's Atty Blasts Feds' 'Sales Over Safety' Oxy Charges
- When Fair Notice Precludes Punitive Damages
- Cox Castle Adds Paul Hastings Enviro Founder In California
- Teligent's 3 Ch. 11 Asset Sales Bring $87M Into Estate
- Teva, Glenmark Must Face Price-Fixing Suit At Same Trial
- 3 Firms Rep ProKidney's $2.64B Go-Public SPAC Deal
- SEC's 'Shadow Trading' Theory Passes Muster With Judge
- PTAB Discretionary Denials Escape High Court Review
- Law360 Names Practice Groups Of The Year
- The Firms That Dominated In 2021
- Pharma Exec's Drug Trafficking Trial Tests Bold Legal Theory
- J&J, New Mexico Ink $44M Opioid Settlement
- Judge Gives J&J Talc Unit's Ch. 11 Dismissal Bid Prominence
- Full Fed. Circ. Won't Revive Juno's $1.2B Cancer Patent Win
- Insys Founder Challenges Opioid Conviction At High Court
- Chinese Cos. Seek Immunity In Dupont IP Criminal Case
- Judge Limits Tolling On Retailer Claims In HIV Generics Suit
- Full Fed. Circ. Told Biogen Ruling Threatens Drug Patents
- Takeda Loses Patent Fight Over Roche's Hemlibra Drug
- Orphan Drug Approval Takeaways From Recent FDA Data
- 'Pharma Bro No More' Shkreli Gets Industry Ban, To Pay $65M
- Ranbaxy Wants Equal Trial Time In 'Bet The Company' MDL
- Health Hires: Manatt, Oscar Health
- Boca Lab Owner Admits To $6.9M Medical Testing Scheme
- Mississippi Senate Advances Medical Pot Legalization Bill
- Takeaways From White Collar Criminal Enforcement In 2021
- Glenmark's Ethics Allegations Against DOJ Rejected
- SEC Wins Claim Atty's Biotech Co. Stock Sales Were 'Charade'
- M&A Ruling Illustrates Limits Of Disclaiming Fraud In Del.
- How In-House Counsel Can Make The Case For Settling Early
- 2nd Circ. Rejects Biotech Investor's Media Defamation Suit
- Sens. Move Forward Nominees For FDA Chief, Labor Dept.
- Deals Rumor Mill: Reddit, Lockheed Martin, ProKidney
- Court OKs Pharma Investors' $12.7M Deal Over Drug Trial
- Alleged Shadow Trader Asks Judge To Halt SEC 'Overreach'
- Cannabis Biopharma Co. Nabs CLO From Suboxone Maker
- Calif. Courts Can't Bar New Prop 65 Suits, 9th Circ. Told
- Activist Investor Starboard Urges Huntsman To Change Board
- Clinical Trial Co. Owner Admits Lying To FDA
- Amazon Buyer Tells 2nd Circ. Diet Pill Suit Must Be Tried
- To Retain Talent, GCs Should Prioritize Mission Statements
- Fed. Circ. Doubts PTAB Erred In Axing Almirall Acne Drug IP
- Arthrex Wants Implant Patent Rematch With New USPTO Chief
- Supplement Co. Inks $1.7M Deal Ending Toxic Drink Claims
- Judge Says Soldiers Should Seek Vax Waiver, Not Sue
- Cooley, Loeb & Loeb Shape $511M Medical Co. SPAC Merger
- Hogan Lovells Lands Baker McKenzie Corporate Pro In Philly
- Ex-Theranos CEO Elizabeth Holmes To Be Sentenced Sept. 26
- 1st Circ. Asks Mass. Court To Weigh In On Heart Valve Suit
- CMS Wants Narrow Coverage For Biogen's Alzheimer's Drug
- Sotomayor, Breyer Scrutinized In Feisty Senate COVID Hearing
- No Sanctions For Eli Lilly In Teva Migraine Drug Patent Row
- Real Estate Rumors: Fifield, Alexandria, Spectrum
- Parents Of Disabled Kids Sue Pa. District To Keep Masks
- Cherokees Drop 'Public Nuisance' Theory In Opioid Bellwether
- Judge Won't Lift Ch. 11 Injunction For J&J Talc Claims
- 7 Ways Patent Litigators Can Leverage Inventor Testimony
- Del. High Court Gets It Right With Opioid Nuisance Ruling
- 9th Circ. Skeptical Of Coverage For Co.'s Opioid Probe Costs
- Top 10 Whistleblowing And Retaliation Events Of 2021
- K&S Adds Former DOJ Litigator To Health Care Practice
- Boston Hospital Workers Urge 1st Circ. To Block Vax Mandate
- 5th Circ. Blasts Court For Sealing Records In Abortion Case
- GoodRx Beats IPO Suit Over Surprise Amazon Competition
- Utah Pot Licensing Suit More Than Adequate, Court Told
- LAPD Workers' COVID-19 Vax Mandate Challenge Tossed
- 3rd Circ. Doubts Merck Worker's Arbitration Award In Pay Row
- Del. High Court Relieves Chubb Of Defending Opioid Suits
- Vineyards' Suit Against Monsanto, BASF Sent To State Court
- Regeneron Wins Access To FDA Docs In Kickback Suit
- High Court Won't Hear Off-Label Ad Suit Against Taro
- Chancery Rejects Fast-Tracking Of $6.7B Arena Merger Suit
- FTC Official Joins Wilson Sonsini's Privacy, Security Practice
- Calif. Gov. Signs Order Barring COVID Test Price-Gouging
- Decision Delayed On Whether Talc Spinoff Stay Shelters J&J
- Ex-Theranos COO May Face Trial Delay Due To COVID Surge
- 11th Circ. Won't Rehear Catalyst's Win In 'Orphan Drug' Case
- 'You Can't Kill Patients': Justices Open To CMS Vaccine Rule
- How Attys For Long Island Counties Notched Opioid Trial Win
- 'Hypothetical' Suit Won't Shield Roche Patents From Review
- Deals Attys Approach JPMorgan Event Cautiously Optimistic
- Venture Firm A16Z Raises $9B For Latest Funds
- Stockholder Sues To Block Pfizer's $6.7B Arena Pharma Buy
- Walgreens' Settlement History Will Stay Out Of SF Opioid Row
- The State Of FDA Regulation Of Software As A Medical Device
- Calif. Says Stopping Pay-For-Delay Ban Went 'Too Far'
- 3rd Circ. Affirms Pharmacy Owner's Tax Fraud Conviction
- Georgia Joins $26B US Opioid Settlement With J&J, Others
- Vitamin C Ruling May Trigger Comity Defense Resurgence
- Purdue Ch. 11 Appeal Can Go To 2nd Circ., NY Judge Rules
- Justices' Texas Abortion Ruling Is Murky On Key Question
- Illumina Investor Sent To Prison During Insider Trading Appeal
- 3 Biotech Firms Kick Off '22 With IPOs Totaling $482M
- Milk Vitamin Patents Surprisingly Soured By Section 101
- Generics Catch A Break With Hikma's Skinny Label Win
- Mallinckrodt Says Ch. 11 Plan Fair For Acthar Claimants
- 3rd Circ. Preview: Constitution, Arbitration Fights Start 2022
- Feds Denied Discovery Stay In Challenge To DOD Vax Mandate
- Workplace Vaccine Rules Take Center Stage At High Court
- Top 5 Drug And Medical Device Legal Issues Of 2021
- States Oppose Purdue's 2nd Circ. Appeal Try In Ch. 11 Case
- Class Attys Get $20M From UnitedHealth ERISA Win
- Hawaiian Airlines Workers Sue To Block Vaccine Mandate
- Mylan Can't Exclude Ex-CEO From EpiPen Antitrust Trial
- How Congressional Oversight May Shift In 2022 And Beyond
- Fla. Court Stays $1B Herbalife Fraud Suit Pending Calif. Deal
- Epstein Becker Adds To Health Care Group In Tenn., Ohio
- Immigrant Says J&J Unit Paid Him Less Than Americans
- Recent Bias Suits Against Law Firms And Lessons For 2022
- Delaware Judge Dismisses Guardant Cancer Test IP Suit
- Fed. Circ. Patent Decisions In 2021: An Empirical Review
- Damages Award Nixed In Child's MMR Vaccine Injury Dispute
- Skadden-Led Stryker Buys $3.09B Health Care Software Maker
- Ex-DEA Official Says Cardinal 'Barely' Monitored For Opioids
- Omicron Surge Reshuffles Patent Trial Plans Once Again
- NJ Judge Pauses SEC's Pharma Insider Trading Suit
- DuPont Escapes NY Water Contamination Claims For Now
- Inside The Top De-SPACs That Didn't Survive 2021's 2nd Half
- Stockholders Sue AmerisourceBergen In Del. Over Opioids
- Teva Urges Judge To Limit Walgreens, CVS Antitrust Claims
- $20M Acquisition Would End Maryland Pot Biz Feud
- Pfizer, Allele Biotech End COVID Vax IP Fight
- 3rd Circ. Says Insurer Must Defend In 5-Hour Energy IP Row
- 4 Takeaways From Elizabeth Holmes' Fraud Verdict
- Nevada Says It's Joining $26B Deal With Opioid Distributors
- Hikma Beats Amarin's 'Skinny Label' Patent Suit
- Texas Abortion Providers Ask Justices To Speed Up SB 8 Suit
- No 'Safe Harbor' For Gene Therapy Found In Hatch-Waxman
- COVID Woes Delay High-Profile Gilead, Samsung IP Trials
- Cannabis Co. Trulieve Escapes Investors' Moldy Pot Suit
- Acthar Claimants Call Mallinckrodt's Ch. 11 Plan Unfair
- Split Fed. Circ. Affirms Novartis' Grip On Gilenya
- Opioid Claims Involving McKinsey Should Be Axed, States Say
- Labcorp To Provide Nursing-Mom Rooms After DOL Probe
- Generic Drug Cos., Takeda Escape Gout Drug Antitrust Suit
- Texas Sues Biden Admin. Over National Guard Vax Mandate
- Nimbus, Bristol-Myers Drop Psoriasis Drug Dispute
- DC Circ. Revives Terror-Funding Case Against AstraZeneca
- Merit Medical's $18.25M Investor Fraud Deal Gets First OK
- GSK Ex-Worker Cops To Trade Secrets Theft
- Boston Scientific Says Dead-End SEC Probe Sinks Stock Suit
- Latham-Led Payroll Software Firm Launches $214M IPO
- Purdue's 2nd Circ. Appeal Request To Get Quick Decision
- U. Of Chicago Prof Pleads Not Guilty To Insider Trading
- 5th Circ. Questions Success Of United Vax Mandate Challenge
- Jury Convicts Ex-Theranos CEO Elizabeth Holmes Of Fraud
- Holmes Jury Tells Judge It's Deadlocked On 3 Of 11 Counts
- Bankruptcy Cases To Watch In 2022
- Associate Hiring Outlook At Law Firms Is Bright For 2022
- Merger Cases, Issues To Watch In 2022
- The Top New Jersey Cases To Watch In 2022
- The Antitrust Conduct Cases To Watch In 2022
- 2022 Trends And Predictions For Patent Litigation
- Trademark Cases To Watch In 2022
- A Blockbuster Year Ahead For Health, Life Sciences Litigation
- Buckle Up: Wild Ride Awaits Health, Life Sci Policy In 2022
- Food And Beverage Policy Trends To Track This Year
- Product Liability Regulation, Legislation To Watch: 2021
- Patent Litigation Trends To Watch In 2022
- 2022 Trials To Watch: Opioids, Oracle And Theranos Redux
- Patent Cases To Watch In 2022
- Product Liability Cases To Watch In 2022
- What To Watch In 2022: The Biggest IP Cases Coming Up